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Background: Human lung tumors are known to be considerably 
heterogeneous in respect to histology across the tumor. The purpose of 
this study was to compare the patient-to patient and intra-patient tumor 
sub-sampling variations in gene expression proﬁles. 
Methods: In this prospective study tumor samples from 20 patients 
who underwent resection for primary lung cancer were collected (4 
squamous cell carcinomas, 11 adeno carcinomas and 5 mixed type 
adeno-squamous carcinomas). They were 16 males and 4 females with 
a median age of 63 years (range 38-69). The pathological stages were 
found to be IA in 4 cases, IB in 10 cases, IIA in 1 case and IIB in 5 
cases. 9 tumors were grade II and 11 tumors grade III. Tissue samples 
were snap frozen in liquid nitrogen within 20 minutes after resection 
and stored at -80°C until analysis. Serial cryo-sections were prepared 
from tissue samples of 4 different sites of the tumor for each patient. 
The ﬁrst and the last section of a series were HE stained and analyzed 
for tumor cell composition. Only samples with more than 50% viable 
tumor cells were used for RNA extraction and subsequent expression 
proﬁling. All RNAs were analysed with Agilent 2100 Bioanalyzer and 
RNA 6000 nano assay kit. The median RIN number was 8.9. Micro-
array analyses were carried out using Affymetrix Human Genome 
U133 Plus 2.0 arrays according to Affymetrix standard protocols. All 
measurements have undergone an extensive QC on probe level (BG 
signal, detection and masking of signal artefacts, etc.) and probe set 
level (model ﬁt quality, afﬁnity proﬁles, RNA degradation analysis, 
etc.). A Roche in-house developed design of the array has been taken 
to eliminate wrong and non-speciﬁc probes. The probe sets have been 
re-designed and re-annotated according to the latest builds of human 
genome and transcriptome. RMA style probe level model (PLM) has 
been used to ﬁt probe-intensity data and estimate probe set expression. 
Results: Inter-patient (patient-to-patient) and intra-patient (tumor site 
to tumor site) variations of gene expression have been determined in a 
uni-variate setting using linear mixed effect model approach. The probe 
sets showing consistently larger intra-patient differences as compared 
with the variation due to workﬂow and that of patient-speciﬁc expres-
sion have been identiﬁed. Considering the probes sets (genes) which 
have found to be responsible for signiﬁcant sampling variations, gene 
ontology analysis has shown that these genes are ‘at random’ and are 
functionally irrelevant. No association to TNM status, tumor stage, pa-
tient gender/age, or other study co-variates has been detected. Several 
genes have been found to be associated with stromal tissue. As also 
conﬁrmed by multi-variate analysis (PCA, PLS), 98% of our probe sets 
showed signiﬁcant patient-to-patient, but no sampling variation.
Conclusions: Gene expression proﬁles based on single tumor tissue 
blocks are representative for the whole tumor, if viable tumor cell con-
tent is equal to or greater 50%. 
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Introduction: Non-small cell lung cancer (NSCLC) is a leading cause 
of cancer mortality in both men and women. One way to improve the 
outcome is to predict survival at diagnosis, in order to select patients 
for the most appropriate treatment. As microarray data have already 
shown to be able to predict the outcome, we hypothesized that further 
reﬁning the prognostic value of these proﬁles would be possible by 
selecting them according to biological characteristics such as prolifera-
tion and hypoxia.
Methods: Several in vitro derived published and unpublished gene-
expression based signatures were tested on a clinical patient microarray 
dataset. This dataset consists of 86 surgically treated NSCLC patients 
of which complete follow-up data was available.
The previously published wound signature, invasiveness gene signature 
(IGS) and Chi signature (hypoxia) as well as an unpublished signature 
for proliferation were evaluated with a signature score. This score 
was deﬁned as the weighted average expression of the genes in the 
signature. This score is used to evaluate the predictive accuracy of the 
various signatures based on Kaplan-Meier survival analysis, log-rank 
tests and multivariate Cox-regression analysis. 
Results: Only two of the evaluated signatures, IGS and proliferation 
signature, had signiﬁcant predictive value in Kaplan-Meier survival 
analyses. Stratifying patients in groups based on the score of these 
signatures resulted in a clear difference in survival, p-values of log-
rank test were 0.039 and 0.018 for the IGS and proliferation signature 
respectively. The areas under the curves for 2-years survival were 0.64 
for the IGS and 0.66 for the proliferation signature. Further multivariate 
Cox-regression analysis with backward stepwise selection procedure 
showed that the proliferation signature was the only signature that was 
an independent predictive parameter (p = 0.030).
Conclusions: The proliferation signature is a predictor for survival of 
surgically treated patients with NSCLC in univariate and multivariate 
analysis, while the IGS was only signiﬁcant in univariate analysis. This 
information may further enable the selection of patients for adjuvant 
therapy as well as give further insight to the mechanisms underlying 
the bad prognosis.
